ACTINIUM PHARMACEUTICALS, INC.

Analyst Reco. Actinium Pharmaceuticals, Inc.

Equities

ATNM

US00507W2061

Market Closed - Nyse Other stock markets 16:00:00 2024-05-08 EDT			5-day change	1st Jan Change
8.71 ^USD	-1.14%		+11.95%	+71.46%

05-07	Actinium Pharmaceuticals, Inc. Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern	CI
04-26	Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Maxim Adjusts Actinium Pharmaceuticals' Price Target to $30 From $20, Maintains Buy Rating	03-19	MT
B. Riley Adjusts Price Target on Actinium Pharmaceuticals to $16 From $20, Maintains Buy Rating	12-11	MT
HSBC Starts Actinium Pharmaceuticals With Buy Rating, Price Target is $11.60	23-09-06	MT
HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $50 From $53, Keeps Buy Rating	23-08-15	MT
B. Riley Raises Actinium Pharmaceuticals' Price Target to $20 From $18, Keeps Buy Rating	23-03-02	MT
William Blair Downgrades Actinium Pharmaceuticals to Market Perform Rating From Outperform	23-02-21	MT
HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $53 From $45, Maintains Buy Rating	22-10-31	MT
B. Riley Raises Actinium Pharmaceuticals' PT to $18 From $16 After Positive Update of Phase 3 SIERRA Trial for Iomab-B, Keeps Buy Rating	22-10-31	MT
Cantor Fitzgerald Initiates Actinium Pharmaceuticals at Overweight with $20 Price Target	22-09-08	MT
B. Riley Securities Initiates Actinium Pharmaceuticals at Buy with $16 Price Target, Says Market Potential for Iomab-B Conditioning Underappreciated	22-08-25	MT
Alliance Global Adjusts Price Target on Actinium Pharmaceuticals to $25 From $20, Maintains Buy Rating	22-04-13	MT
Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML	21-12-14	CI
ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $45 From $57, Maintains Buy Rating	21-08-03	MT
ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $57 From $65, Maintains Buy Rating	21-04-01	MT
Actinium Pharmaceuticals, Inc. Reports 67% Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH	20-12-08	CI
ACTINIUM PHARMACEUTICALS : Alliance Global Starts Actinium Pharmaceuticals at Buy With $25 Price Target	20-11-05	MT
Actinium Pharmaceuticals : Reports 100% Remission Rate in Cohort of Phase 1 Study of Actimab-A CLAG; Shares Rise 10%	20-11-04	MT
Actinium Pharmaceuticals, Inc. Announces 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML	20-11-04	CI
Actinium Pharmaceuticals, Inc. Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting	19-12-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW